Kerri-Anne Mullen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kerri-Anne Mullen has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Robert D. Reid
Division of Cardiac Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Canada
7 shared publications - Andrew L. Pipe
Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
4 shared publications Hassan Mir
4 shared publications- Heather Tulloch
University of Ottawa Heart Institute , Ottawa, Ontario
4 shared publications - Jennifer L. Reed
University of Ottawa Heart Institute , Ottawa, Ontario
4 shared publications Robert D Reid
Division of Cardiac Prevention & Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
4 shared publications
Latest Publications
- 3 August 2026
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (11)
Ending Tobacco Use Without Redistributing Tobacco Harm
- 3 August 2026
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (11)
Ending Tobacco Use Without Redistributing Tobacco Harm
- Open Access
- 14 May 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e71875
Understanding How a Digital Platform for Chronic Disease Management Can Enable and Limit Patient Self-Care: Qualitative Study
Background: A growing segment of the population requires ongoing care and support for managing their chronic diseases. Digital platforms for self-management are rapidly emerging to meet this need, but patients’ experiences with these platforms vary significantly. This may be due to the complexity and flexibility of digital platforms, where the wide array of available features can generate unexpected impacts. Objective: This study aims to explore how a digital platform can both enable and limit patients with a chronic disease in managing their own health. Methods: We conducted semistructured qualitative interviews with patients to better understand their experience of using a digital platform for self-managing their chronic diseases. Patients who had been using a digital platform (the Chronic Care Platform) for at least 1 month were invited to participate. Twenty-four patients were recruited and interviewed in person or by phone. The collected data were analyzed using template analysis, which is a type of thematic analysis that allows inductive identification of themes from data and deductive application of theory-informed themes. We leveraged Self-Care Theory to understand how patients’ motivation to use the platform and their subsequent use of its features generated perceived value and challenges in achieving this value. Results: The platform was shown to support patients’ development of core self-care abilities (cognitive, psychosocial, and sociocultural abilities) and self-care behaviors (maintenance, monitoring, management), but it did not provide any support to the development of physiological abilities. Moreover, results indicate important limitations in the way in which the digital platform supported all self-care abilities and behaviors—in particular, self-care management. Hence, while the platform was viewed as valuable overall, patients reported several challenges in effectively using the Chronic Care Platform for self-care. Conclusions: Digital platforms for chronic disease management can enhance patient self-care by providing valuable resources and support for reinforcing desired behaviors. However, gaps in platform features can limit patients’ ability to comprehensively care for themselves. This study shows that relating platform features to specific dimensions of self-care can help identify missing features, providing a fine-grained understanding of how a given platform is generating positive impacts and how it may be improved to fully support self-care.
- 14 May 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28 (1) , e71875
Open AccessUnderstanding How a Digital Platform for Chronic Disease Management Can Enable and Limit Patient Self-Care: Qualitative Study
Background: A growing segment of the population requires ongoing care and support for managing their chronic diseases. Digital platforms for self-management are rapidly emerging to meet this need, but patients’ experiences with these platforms vary significantly. This may be due to the complexity and flexibility of digital platforms, where the wide array of available features can generate unexpected impacts. Objective: This study aims to explore how a digital platform can both enable and limit patients with a chronic disease in managing their own health. Methods: We conducted semistructured qualitative interviews with patients to better understand their experience of using a digital platform for self-managing their chronic diseases. Patients who had been using a digital platform (the Chronic Care Platform) for at least 1 month were invited to participate. Twenty-four patients were recruited and interviewed in person or by phone. The collected data were analyzed using template analysis, which is a type of thematic analysis that allows inductive identification of themes from data and deductive application of theory-informed themes. We leveraged Self-Care Theory to understand how patients’ motivation to use the platform and their subsequent use of its features generated perceived value and challenges in achieving this value. Results: The platform was shown to support patients’ development of core self-care abilities (cognitive, psychosocial, and sociocultural abilities) and self-care behaviors (maintenance, monitoring, management), but it did not provide any support to the development of physiological abilities. Moreover, results indicate important limitations in the way in which the digital platform supported all self-care abilities and behaviors—in particular, self-care management. Hence, while the platform was viewed as valuable overall, patients reported several challenges in effectively using the Chronic Care Platform for self-care. Conclusions: Digital platforms for chronic disease management can enhance patient self-care by providing valuable resources and support for reinforcing desired behaviors. However, gaps in platform features can limit patients’ ability to comprehensively care for themselves. This study shows that relating platform features to specific dimensions of self-care can help identify missing features, providing a fine-grained understanding of how a given platform is generating positive impacts and how it may be improved to fully support self-care.
- Open Access
- 30 July 2025
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 23 (July) , 1-6
Vaping is associated with increased length of stay among cardiac inpatients
Introduction: The rapid increase in e-cigarette use, especially among youth, raises significant health concerns. Understanding their impact on high-risk populations, such as those with cardiovascular disease, is crucial for improving patient outcomes and reducing healthcare utilization. The aim...
- 30 July 2025
- Published by European Publishing in Tobacco Induced Diseases
- Vol. 23 (July) , 1-6
Open AccessVaping is associated with increased length of stay among cardiac inpatients
Introduction: The rapid increase in e-cigarette use, especially among youth, raises significant health concerns. Understanding their impact on high-risk populations, such as those with cardiovascular disease, is crucial for improving patient outcomes and reducing healthcare utilization. The aim...
- Open Access
- 1 June 2025
- Published by Wolters Kluwer Health in O&G Open
- Vol. 2 (3) , e087
Association Between a Technology-Enabled Postpartum Program and Cardiovascular Disease Risk Reduction in Women With Prior Hypertensive Disorders of Pregnancy
BACKGROUND: To test the association between a behavior-change, risk-reduction intervention and cardiovascular disease (CVD) risk scores in women with previous hypertensive disorders of pregnancy (HDP). METHODS: We completed a prospective, single-arm comparative pre–post study of women with recent HDP. The intervention was the CardioPrevent Postpartum Program, which involves health behavior-change coaches who counseled participants in 17 sessions over 12 months regarding behavioral changes (smoking, nutrition, physical activity), and worked with primary-care practitioners to optimize medical management of underlying risk factors (hypertension, dyslipidemia, diabetes mellitus). We measured changes in global risk scores (lifetime, Framingham Risk score) and clinical, psychosocial, and health behavior outcomes at 12 months compared with baseline. RESULTS: Overall, 190 women were enrolled. Absolute reductions in Framingham and Lifetime Risk Scores at 12 months postintervention were 53.7% and 22.6%, respectively (both P≤.001). The intervention was associated with decreases in body weight (81.7±19.4 vs 74.1±19.8 kg, P<.001), waist circumference (96.9±15.5 vs 89.5±14.9 cm, P<.001), hypertension (50% vs 4.3%), and metabolic syndrome (53.6% vs 43.5%) between baseline and 12 months, but fasting plasma glucose and hemoglobin A1c were unchanged. Triglycerides, low-density lipoprotein cholesterol, and total cholesterol decreased; however, high-density lipoprotein cholesterol also decreased. We observed a 40.6% absolute reduction in postpartum depression, a 28.2% absolute reduction in anxiety, and a 67.9% absolute reduction in perceived stress at 12 months compared with baseline. Compared with baseline, the intervention was associated with a higher proportion of participants who met guideline recommendations for physical activity levels (48.4% vs 75.2%, P<.001), fruit and vegetable intake (21.5% vs 44.4%, P<.001), and medication adherence (29.4% vs 48.7%, P<.001) at 12 months. CONCLUSION: This behavior-change, risk-reduction intervention was associated with improvements in CVD risk factors at 12 months after initiation. Multidisciplinary health behavior-change programs may be effective CVD risk-reduction strategies for women with previous HDP.
- 1 June 2025
- Published by Wolters Kluwer Health in O&G Open
- Vol. 2 (3) , e087
Open AccessAssociation Between a Technology-Enabled Postpartum Program and Cardiovascular Disease Risk Reduction in Women With Prior Hypertensive Disorders of Pregnancy
BACKGROUND: To test the association between a behavior-change, risk-reduction intervention and cardiovascular disease (CVD) risk scores in women with previous hypertensive disorders of pregnancy (HDP). METHODS: We completed a prospective, single-arm comparative pre–post study of women with recent HDP. The intervention was the CardioPrevent Postpartum Program, which involves health behavior-change coaches who counseled participants in 17 sessions over 12 months regarding behavioral changes (smoking, nutrition, physical activity), and worked with primary-care practitioners to optimize medical management of underlying risk factors (hypertension, dyslipidemia, diabetes mellitus). We measured changes in global risk scores (lifetime, Framingham Risk score) and clinical, psychosocial, and health behavior outcomes at 12 months compared with baseline. RESULTS: Overall, 190 women were enrolled. Absolute reductions in Framingham and Lifetime Risk Scores at 12 months postintervention were 53.7% and 22.6%, respectively (both P≤.001). The intervention was associated with decreases in body weight (81.7±19.4 vs 74.1±19.8 kg, P<.001), waist circumference (96.9±15.5 vs 89.5±14.9 cm, P<.001), hypertension (50% vs 4.3%), and metabolic syndrome (53.6% vs 43.5%) between baseline and 12 months, but fasting plasma glucose and hemoglobin A1c were unchanged. Triglycerides, low-density lipoprotein cholesterol, and total cholesterol decreased; however, high-density lipoprotein cholesterol also decreased. We observed a 40.6% absolute reduction in postpartum depression, a 28.2% absolute reduction in anxiety, and a 67.9% absolute reduction in perceived stress at 12 months compared with baseline. Compared with baseline, the intervention was associated with a higher proportion of participants who met guideline recommendations for physical activity levels (48.4% vs 75.2%, P<.001), fruit and vegetable intake (21.5% vs 44.4%, P<.001), and medication adherence (29.4% vs 48.7%, P<.001) at 12 months. CONCLUSION: This behavior-change, risk-reduction intervention was associated with improvements in CVD risk factors at 12 months after initiation. Multidisciplinary health behavior-change programs may be effective CVD risk-reduction strategies for women with previous HDP.
- Top Cited PapersOpen Access
- 26 February 2025
- Published by BMJ in Tobacco Control
- Vol. 35 (3) , 382-390
Vaping cessation interventions: a systematic review and meta-analysis
Objective Electronic nicotine delivery systems (ENDS), such as e-cigarettes, have surged in popularity. While long-term risks remain unclear, known dangers include nicotine addiction, E-cigarette or Vaping Use-Associated Lung Injury and potential extrapulmonary effects on the heart, immune system and neurodevelopment. Addressing ENDS addiction may require strategies akin to smoking cessation. However, evidence is lacking; there are no currently approved vaping-cessation aids. The objective of this review is to summarise the available literature addressing interventions for vaping cessation. Data sources and study selection A librarian-assisted search was conducted in MEDLINE, Embase and Scopus, as well as preprints in Europe PMC, Open Science Framework, and the grey literature searches until January 2024. Six included studies used self-report methods to determine the abstinence rate, while one study used cotinine-level-verified self-reported abstinence. We included randomised controlled trials (RCTs) that examine ‘rates of vaping cessation’ outcomes. An intention-to-treat approach was used for data extraction, and random-effects meta-analyses models were applied. Data synthesis Seven RCTs were included, which studied pharmacological therapy, digital interventions and/or educational content. The primary meta-analyses demonstrated a statistically significant increase in the odds of achieving 7-day point prevalence abstinence (PPA) (OR 1.52, 95% CI 1.15 to 2.01, number of participants=3244, moderate-certainty) and continuous abstinence (OR 2.71, 95% CI 1.31 to 5.61, number of participants=164, low-certainty) following intervention. A non-significant increase in odds was noted at 30-day PPA (OR 1.32, 95% CI 0.72 to 2.42, number of participants=1994, very low certainty). Conclusions Vaping cessation interventions increase 7-day PPA rates at 1–12 months follow-up and this was consistent across prespecified subgroup analyses of the intervention type, outcome and duration of follow-up. More high-quality studies with reproducible findings are needed to enhance the certainty of the evidence and guide clinical interventions. PROSPERO registration number CRD42022383670.
- 26 February 2025
- Published by BMJ in Tobacco Control
- Vol. 35 (3) , 382-390
Top Cited PapersOpen AccessVaping cessation interventions: a systematic review and meta-analysis
Objective Electronic nicotine delivery systems (ENDS), such as e-cigarettes, have surged in popularity. While long-term risks remain unclear, known dangers include nicotine addiction, E-cigarette or Vaping Use-Associated Lung Injury and potential extrapulmonary effects on the heart, immune system and neurodevelopment. Addressing ENDS addiction may require strategies akin to smoking cessation. However, evidence is lacking; there are no currently approved vaping-cessation aids. The objective of this review is to summarise the available literature addressing interventions for vaping cessation. Data sources and study selection A librarian-assisted search was conducted in MEDLINE, Embase and Scopus, as well as preprints in Europe PMC, Open Science Framework, and the grey literature searches until January 2024. Six included studies used self-report methods to determine the abstinence rate, while one study used cotinine-level-verified self-reported abstinence. We included randomised controlled trials (RCTs) that examine ‘rates of vaping cessation’ outcomes. An intention-to-treat approach was used for data extraction, and random-effects meta-analyses models were applied. Data synthesis Seven RCTs were included, which studied pharmacological therapy, digital interventions and/or educational content. The primary meta-analyses demonstrated a statistically significant increase in the odds of achieving 7-day point prevalence abstinence (PPA) (OR 1.52, 95% CI 1.15 to 2.01, number of participants=3244, moderate-certainty) and continuous abstinence (OR 2.71, 95% CI 1.31 to 5.61, number of participants=164, low-certainty) following intervention. A non-significant increase in odds was noted at 30-day PPA (OR 1.32, 95% CI 0.72 to 2.42, number of participants=1994, very low certainty). Conclusions Vaping cessation interventions increase 7-day PPA rates at 1–12 months follow-up and this was consistent across prespecified subgroup analyses of the intervention type, outcome and duration of follow-up. More high-quality studies with reproducible findings are needed to enhance the certainty of the evidence and guide clinical interventions. PROSPERO registration number CRD42022383670.
- Open Access
Barriers and facilitators of cardiovascular disease prevention services for women with prior gestational diabetes or hypertensive disorders of pregnancy in low-income, middle-income and high-income settings: a scoping review protocol
Introduction Women with previous pregnancy-related cardiovascular risk indicators, including gestational diabetes mellitus (GDM) and hypertensive disorders of pregnancy (HDP), have an increased risk of future cardiovascular disease (CVD). Although CVD screening and preventive care beginning in the early postpartum period are recommended, certain barriers limit access to such services. We plan to conduct a scoping review of the literature to explore and summarise evidence on the barriers and facilitators of postpartum CVD preventive services in women with a history of GDM and HDP. Methods and analysis This scoping review will be conducted in line with the Arksey and O’Malley’s (2005) methodological framework and the Joanna Briggs Institute guidance for conducting a systematic scoping review and will follow the Evidence for Policy and Practice Information and the Coordinating Centre at the Institute of Education guidelines. The review results will be reported using the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist. We will search the following databases: Medline, Embase and CINAHL. We will conduct grey literature searches for registered dissertations and theses. Inclusion and exclusion criteria will be kept broad. Qualitative and quantitative studies published in English or French that investigated and reported percieved barriers or facilitators to postpartum CVD screening and preventive care among women with previous GDM and HDP will be included. Individual, interpersonal, organizational, and system level factors will be reported. Qualitative findings will be summarised narratively, and quantitative findings will be absorbed within the themes using the multisource synthesis method. Ethics and dissemination This review represents one objective of a larger project that was reviewed by the Ottawa Health Sciences Network Research Ethics Board (QI-184). We will disseminate knowledge emanating from this review through open-access publication, presentation/public forums on women’s cardiovascular health, women’s CVD prevention forums and social media. We will also present the findings of this review at the annual meeting of the Canadian Women’s Heart Health Alliance.
Open AccessBarriers and facilitators of cardiovascular disease prevention services for women with prior gestational diabetes or hypertensive disorders of pregnancy in low-income, middle-income and high-income settings: a scoping review protocol
Introduction Women with previous pregnancy-related cardiovascular risk indicators, including gestational diabetes mellitus (GDM) and hypertensive disorders of pregnancy (HDP), have an increased risk of future cardiovascular disease (CVD). Although CVD screening and preventive care beginning in the early postpartum period are recommended, certain barriers limit access to such services. We plan to conduct a scoping review of the literature to explore and summarise evidence on the barriers and facilitators of postpartum CVD preventive services in women with a history of GDM and HDP. Methods and analysis This scoping review will be conducted in line with the Arksey and O’Malley’s (2005) methodological framework and the Joanna Briggs Institute guidance for conducting a systematic scoping review and will follow the Evidence for Policy and Practice Information and the Coordinating Centre at the Institute of Education guidelines. The review results will be reported using the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist. We will search the following databases: Medline, Embase and CINAHL. We will conduct grey literature searches for registered dissertations and theses. Inclusion and exclusion criteria will be kept broad. Qualitative and quantitative studies published in English or French that investigated and reported percieved barriers or facilitators to postpartum CVD screening and preventive care among women with previous GDM and HDP will be included. Individual, interpersonal, organizational, and system level factors will be reported. Qualitative findings will be summarised narratively, and quantitative findings will be absorbed within the themes using the multisource synthesis method. Ethics and dissemination This review represents one objective of a larger project that was reviewed by the Ottawa Health Sciences Network Research Ethics Board (QI-184). We will disseminate knowledge emanating from this review through open-access publication, presentation/public forums on women’s cardiovascular health, women’s CVD prevention forums and social media. We will also present the findings of this review at the annual meeting of the Canadian Women’s Heart Health Alliance.
- Open Access
- 14 August 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 131 (7) , 1178-1185
Cost-effectiveness of point of care smoking cessation interventions in oncology clinics
Background: We examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care. Methods: A decision analytic model was completed from the healthcare payer’s perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (n = 1040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC + SSM), including nicotine replacement therapy, varenicline, or bupropion. Primary outcomes were incremental cost per quit (ICQ) and incremental cost per cancer treatment failure avoided (ICTFA). Results: The ICQ was $C143 and ICTFA $C1193 for standard OMSC. The ICQ was $C503 and ICTFA was $C5952 for OMSC + SSM. The number needed to treat (NNT) to produce one quit was 9 for standard OMSC and 4 for OMSC + SSM, and the NNT to avoid one first-line treatment failure was 78 for OMSC and 45 for OMSC + SSM. Both were cost-effective in 100% of 1000 simulations. Conclusions: Given the high clinical benefits and low incremental costs, systematic smoking cessation interventions should be a standard component of first-line cancer treatment.
- 14 August 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 131 (7) , 1178-1185
Open AccessCost-effectiveness of point of care smoking cessation interventions in oncology clinics
Background: We examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care. Methods: A decision analytic model was completed from the healthcare payer’s perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (n = 1040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC + SSM), including nicotine replacement therapy, varenicline, or bupropion. Primary outcomes were incremental cost per quit (ICQ) and incremental cost per cancer treatment failure avoided (ICTFA). Results: The ICQ was $C143 and ICTFA $C1193 for standard OMSC. The ICQ was $C503 and ICTFA was $C5952 for OMSC + SSM. The number needed to treat (NNT) to produce one quit was 9 for standard OMSC and 4 for OMSC + SSM, and the NNT to avoid one first-line treatment failure was 78 for OMSC and 45 for OMSC + SSM. Both were cost-effective in 100% of 1000 simulations. Conclusions: Given the high clinical benefits and low incremental costs, systematic smoking cessation interventions should be a standard component of first-line cancer treatment.